Nirogacestat in Patients With Kaposi Sarcoma

This phase II trial studies how well nirogacestat works in treating patients with skin Kaposi sarcoma (KS). Several anti-cancer drugs work well in treating KS, but there is no treatment that cures KS. Nirogacestat binds to a protein called gamma secretase, which blocks the activation of other proteins called Notch receptors. Blocking these proteins may help keep tumor cells from growing and may kill them. Nirogacestat is a type of gamma secretase inhibitor. Nirogacestat may be effective in shrinking the size of KS lesions and reducing the spread of lesions.

NCT Number	NCT07539454
Lead Sponsor	AIDS Malignancy Consortium Collaborators: National Cancer Institute (NCI)
Conditions	AIDS-Related Kaposi Sarcoma, Skin Kaposi Sarcoma
Enrollment	28 participants
Start Date	2026-09-17
Primary Completion	2030-02-17 (estimated)
Study Completion	2030-02-17 (estimated)
Updated on ClinicalTrials.gov	2026-05-28